US firm Aisling Capital closes life sciences fund on $650m

The fund, which was launched in Q4 2008, will invest primarily in companies developing pharmaceutical, biopharmaceutical and medical products, and in businesses that provide drug development, manufacturing and other services to the healthcare industry.

Dennis Purcell, senior managing partner of Aisling Capital, said, 'We appreciate the support of our existing and new limited partners, particularly during these times of market turbulence. We believe the next several years will be a critical period for the life sciences industry, in which multiple forces will converge to create opportunities for the prepared investor.'

Aisling Capital invests in both private and public companies utilising various investment structures. With $1.6bn under management, the firm will also continue to manage the Perseus-Soros BioPharmaceutical Fund and Aisling Capital II.

Copyright © 2009 AltAssets